Form 8-K · Current Report · Filed 2026-08-06
Halozyme Reports Record Q2 2026 Results and Raises Full-Year Guidance
Halozyme Therapeutics, Inc. reported record financial results for the second quarter of 2026, with total revenue increasing 48% year-over-year to $481 million and royalty revenue rising 50% to $308 million. The company also raised its full-year 2026 financial guidance, anticipating total revenue between $1.835 billion and $1.910 billion, representing growth of 31% to 37% over 2025. Additionally, Halozyme signed five new ENHANZE and Hypercon collaborations YTD 2026, exceeding its goal of three for the full year.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-26-000103
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$83.59
Next session
+23.4%
Since filing
+31.9%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, HALO insiders reported 36 Form 4 transactions — net selling of $7.4M.
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.